TXG Stock Analysis: 10X Genomics | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 10.508m USD | 12M Return: 548.2% | US88025U1097 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 311M
Qual. Beats: 0
Rev. Trend: 56.2%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
10x Genomics, Inc. (NASDAQ: TXG) is a U.S.-based life sciences tools company headquartered in Pleasanton, California, that develops and sells instruments, consumables, and software for analyzing biological systems. The company operates globally, serving academic, government, biopharmaceutical, and biotechnology institutions. It was incorporated in 2012 under the name 10X Technologies, Inc. and went public in September 2019.
The companys product portfolio centers on three core platforms: the Chromium single-cell analysis platform (including the Chromium X Series and microfluidic chips), the Visium spatial analysis platform (featuring the Visium CytAssist instrument and HD gene expression assays), and the Xenium in situ analysis platform. These offerings reflect a classic razor-and-blade business model common in the life sciences tools sector, where instruments are placed with customers and recurring revenue is generated through consumables such as chips, kits, slides, and reagents.
10x Genomics complements its hardware and consumables with a software ecosystem that includes Cell Ranger for single-cell RNA sequencing data processing, Loupe Browser for data visualization, and Xenium Explorer for in situ analysis. The company is classified within the GICS Health Care sector under the Life Sciences Tools & Services sub-industry, a segment characterized by high R&D intensity and reliance on academic and biopharma research demand.
- Xenium platform adoption accelerates spatial analysis revenue growth
- NIH grant funding pressure weighs on academic customer orders
- China sales decline amid geopolitical tensions and export controls
| Net Income: -75.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 5.99 > 1.0 |
| NWC/Revenue: 90.15% < 20% (prev 84.32%; Δ 5.83% < -1%) |
| CFO/TA 0.12 > 3% & CFO 127.1m > Net Income -75.1m |
| Net Debt (-473.2m) to EBITDA (37.7m): -12.56 < 3 |
| Current Ratio: 5.69 > 1.5 & < 3 |
| Outstanding Shares: last quarter (130.0m) vs 12m ago 4.40% < -2% |
| Gross Margin: 70.03% > 18% (prev 69.50%; Δ 0.53% > 0.5%) |
| Asset Turnover: 61.38% > 50% (prev 65.76%; Δ -4.38% > 0%) |
| Interest Coverage Ratio: -0.12 > 6 (EBIT TTM -8.26m / Interest Expense TTM 66.6m) |
| A: 0.54 (Total Current Assets 674.7m - Total Current Liabilities 118.5m) / Total Assets 1.03b |
| B: -1.50 (Retained Earnings -1.54b / Total Assets 1.03b) |
| C: -0.01 (EBIT TTM -8.26m / Avg Total Assets 1.01b) |
| D: 4.04 (Book Value of Equity 825.5m / Total Liabilities 204.5m) |
| Altman-Z'' = 2.84 = A |
| DSRI: 0.44 (Receivables 50.6m/119.1m, Revenue 616.9m/644.5m) |
| GMI: 0.99 (GM 69.50% / 70.03%) |
| AQI: 3.62 (AQ_t 0.08 / AQ_t-1 0.02) |
| SGI: 0.96 (Revenue 616.9m / 644.5m) |
| TATA: -0.20 (NI -75.1m - CFO 127.1m) / TA 1.03b) |
| Beneish M = -1.99 (Cap -4..+1) = B |
As of October 13, 2026, the stock is trading at USD 75.19 with a total of 4,080,287 shares traded. Over the past week, the price has changed by -23.07%, over one month by +7.25%, over three months by +80.01% and over the past year by +548.19%.
Current recommended Stop Loss: 66.50 (which is 11.6% or 1.3 ATR below the current price).
10X Genomics has received a consensus analysts rating of 3.68. Therefore, it is recommended to hold TXG.
- StrongBuy: 6
- Buy: 1
- Hold: 12
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 69.5 | -7.6% |
P/E Forward = 1250.0
P/S = 17.0332
P/B = 11.9347
Revenue TTM = 616.9m USD
EBIT TTM = -8.26m USD
EBITDA TTM = 37.7m USD
Long Term Debt = 66.8m USD (estimated: total debt 78.8m - short term 12.0m)
Short Term Debt = 12.0m USD (from shortTermDebt, last quarter)
Debt = 78.8m USD (from shortLongTermDebtTotal, last quarter) (leases 78.8m already included)
Net Debt = -473.2m USD (calculated: Debt 78.8m - CCE 552.0m)
Enterprise Value = 10.0b USD (10.5b + Debt 78.8m - CCE 552.0m)
Interest Coverage Ratio = -0.12 (Ebit TTM -8.26m / Interest Expense TTM 66.6m)
EV/FCF = 82.63x (Enterprise Value 10.0b / FCF TTM 121.4m)
FCF Yield = 1.21% (FCF TTM 121.4m / Enterprise Value 10.0b)
FCF Margin = 19.68% (FCF TTM 121.4m / Revenue TTM 616.9m)
Net Margin = -12.18% (Net Income TTM -75.1m / Revenue TTM 616.9m)
Gross Margin = 70.03% ((Revenue TTM 616.9m - Cost of Revenue TTM 184.9m) / Revenue TTM)
Gross Margin QoQ = 74.48% (prev 70.39%)
Tobins Q-Ratio = 9.74 (Enterprise Value 10.0b / Total Assets 1.03b)
Interest Expense / Debt = 84.56% (Interest Expense 66.6m / Debt 78.8m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -6.52m (EBIT -8.26m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.69 (Total Current Assets 674.7m / Total Current Liabilities 118.5m)
Debt / Equity = 0.10 (Debt 78.8m / totalStockholderEquity, last quarter 825.5m)
Debt / EBITDA = -12.56 (Net Debt -473.2m / EBITDA 37.7m)
Debt / FCF = -3.90 (Net Debt -473.2m / FCF TTM 121.4m)
Total Stockholder Equity = 805.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -7.47% (Net Income -75.1m / Total Assets 1.03b)
RoE = -9.33% (Net Income TTM -75.1m / Total Stockholder Equity 805.3m)
RoCE = -0.95% (EBIT -8.26m / Capital Employed (Equity 805.3m + L.T.Debt 66.8m))
RoIC = -0.73% (negative operating profit) (NOPAT -6.52m / Invested Capital 892.7m)
WACC = 12.74% (E(10.5b)/V(10.6b) * Re(12.84%) + (debt cost/tax rate unavailable))
Discount Rate = 12.84% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 99.08 | Cagr: 3.85%
[DCF] Terminal Value 65.11% ; FCFF base≈95.6m ; Y1≈109.6m ; Y5≈161.3m
[DCF] Fair Price = 15.26 (EV 1.36b - Net Debt -473.2m = Equity 1.83b / Shares 120.2m; r=12.74% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.45 | # QB: 0
Revenue Correlation: 56.20 | Revenue CAGR: 1.58% | SUE: 0.38 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.02 | Chg30d=N/A | Revisions=+40% | Analysts=2
EPS current Year (2026-12-31): EPS=0.04 | Chg30d=-65.05% | Revisions=+25% | GrowthEPS=-70.2% | GrowthRev=-3.5%
EPS next Year (2027-12-31): EPS=0.08 | Chg30d=-62.27% | Revisions=+25% | GrowthEPS=+109.1% | GrowthRev=+9.7%
[Analyst] Revisions Ratio: +57% (up=4, down=0)